Orforglipron, Cagrilintide, and the Libre Assist

Welcome back to Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives!In this episode of Diabetes Dialogue, cohosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at the University Hospitals Diabetes and Metabolic Care Center, review major therapeutic and technology updates in diabetes care, beginning with newly announced topline phase 3 data for orforglipron, the first oral nonpeptide GLP-1 receptor agonist submitted to the FDA.Key Episode Timestamps00:00:01 Intro00:00:15 Orforglipron and ATTAIN-MAINTAIN00:07:33 Cagrelinitide with semaglutide at the FDA00:10:26 The Libre Assist00:18:31 Outro